Product details

This is part of a case series. In 2001 Dr Brian Brink, Senior Vice President of Anglo American, a massive South African mining conglomerate, was debating how to confront the ravages that extremely high HIV/AIDS rates were taking on Anglo's workforce and overall productivity. According to the firm's best estimates, 21 percent of Anglo American's workforce was HIV-positive in 2001. Specifically Dr Brink was debating the merits of adding a potentially costly antiretroviral component to the existing HIV/AIDS program. The case looks at the economic impact of HIV/AIDS on the Anglo workforce; examines the strategic, cost/benefit, and corporate social responsibility issues involved in offering the antiretroviral drug program to workers; contrasts Anglo's programs with its key competitors; and considers the financial, implementation, and political challenges involved in launching the antiretroviral program. Case (B) is set in 2003 and provides an update of how the program has fared since it was initially announced.